Active Biotech has commenced enrollment for a clinical Phase I combination study of its candidate drug, Anyara, with the cancer (chemotherapy) drug, Taxotere. The study is designed to evaluate the two drugs in combination as a treatment for non-small cell lung cancer.
This dose-escalation study, expected to include between 20 and 30 patients, will examine the response to increasing doses of Anyara in combination with a fixed dose of Taxotere. Taxotere will be administered according to the established dosing schedule; Anyara will be dosed at levels expected to have an antitumor effect.
